Skip to main content

Advertisement

Table 2 Adjusted HbA1c reduction over 12 months in patients switching from NPH to glargine*

From: Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study

Variable Type 1 (n = 304) Type 2 (n = 397)
No. Δ HbA 1c (%) p-value No. Δ HbA 1c (%) p-value
Overall 304 -0.38 <0.001 397 -0.31 <0.001
HbA1c by baseline level       
   ≥ 7% 259 -0.42 <0.001 327 -0.36 <0.001
   ≥ 8% 186 -0.57 <0.001 271 -0.47 <0.001
   ≥ 9% 107 -0.96 <0.001 162 -0.69 <0.001
   ≥ 10% 53 -1.07 <0.001 71 -0.97 <0.001
  1. *Adjusted for significantly correlated demographic and clinical covariates including concomitant use of bolus, age, weight, hypoglycaemia, and baseline HbA1c (in the 3 months prior to insulin initiation).
  2. †p-values by the paired t-test for difference in mean HbA1c following switch from NPH to glargine.